Carfilzomib: en combinació amb lenalidomida i dexametasona o dexametasona sola, per al tractament de pacients adults amb mieloma múltiple que han rebut com a mínim un tractament previ
Abstract
Multiple myeloma (MM) is a neoplastic disorder. With current treatments it is considered an incurable clinical condition. The main goals of the treatment are to prolong survival and maintain the quality of life by controlling the illness and the relief of symptoms. There is a medical need not covered by better treatments capable of delaying the progression of the MM, given the absence of a healing treatment and that in the long run patients will become refractory to treatment. The choice of treatment in the context of relapse depends on many parameters such as age, functional status, comorbidities, type, efficacy and tolerance of previous treatment, number of treatment lines, options Of remaining available treatment, the interval from the last treatment and the type of relapse
Keywords
Carfilzomib; Lenalidomide; Adult patients
Bibliographic citation
Carfilzomib: en combinació amb lenalidomida i dexametasona o dexametasona sola, per al tractament de pacients adults amb mieloma múltiple que han rebut com a mínim un tractament previ. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3661This item appears in following collections
The following license files are associated with this item: